Additional file 1: Figure S1. of Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism
收藏资源简介：
Effect of statin therapy and diet on body weight and glucose metabolism. Figure S2. Changes in the gut microbiome composition in response to statins of mice fed with ND. Figure S3. Changes in the gut microbiome composition in response to high fat diet. Figure S4. Statin therapy does not potentiate the diet-induced intestinal dysbiosis. Figure S5. Variation of LBP levels in serum in response to statin therapy and diet. Figure S6. Metagenome prediction based on the community composition of the gut microbiota of wild type mice treated with statins and normal diet. Figure S7. Metagenome prediction based on the community composition of the gut microbiota of wild type mice treated with statins and high fat diet. Figure S8. Metagenome prediction based on the community composition of the gut microbiota of wild type mice treated with statins and high fat diet. Figure S9. Effect of statin therapy and diet on body weight and glucose metabolism in Pxr-/- mice. Figure S10. Effect of statin therapy on the gut microbiota of Pxr-/- mice. Figure S11. Changes in the gut microbial community in response to statins differ based on the activity of PXR. Figure S12. Variation of LBP levels in serum of Pxr-/- mice in response to statin therapy. Figure S13. Metagenome prediction based on the community composition of the gut microbiota of Pxr-/- mice treated with statins. Figure S14. Production of short chain fatty acid by the gut microbiota of Pxr-/- mice treated with statins. Figure S15. PXR modulates the changes in gene expression induced by statins. (ZIP 5 mb)
他汀类药物治疗与膳食对体重及糖代谢的影响。图S2：饲喂正常膳食（normal diet, ND）的小鼠在他汀类药物干预下肠道微生物组组成的变化。图S3：高脂膳食干预下肠道微生物组组成的变化。图S4：他汀类药物治疗不会加剧膳食诱导的肠道菌群失调。图S5：血清脂多糖结合蛋白（lipopolysaccharide-binding protein, LBP）水平在他汀类药物治疗与膳食干预下的变化。图S6：基于饲喂正常膳食、经他汀类药物处理的野生型小鼠肠道微生物群落组成的宏基因组预测。图S7：基于饲喂高脂膳食、经他汀类药物处理的野生型小鼠肠道微生物群落组成的宏基因组预测。图S8：基于饲喂高脂膳食、经他汀类药物处理的野生型小鼠肠道微生物群落组成的宏基因组预测。图S9：他汀类药物治疗与膳食对Pxr基因敲除（Pxr-/-）小鼠体重及糖代谢的影响。图S10：他汀类药物治疗对Pxr基因敲除（Pxr-/-）小鼠肠道菌群的影响。图S11：他汀类药物干预下肠道微生物群落的变化因PXR（pregnane X receptor）活性不同而存在差异。图S12：Pxr基因敲除（Pxr-/-）小鼠血清脂多糖结合蛋白水平在他汀类药物治疗下的变化。图S13：基于经他汀类药物处理的Pxr基因敲除（Pxr-/-）小鼠肠道微生物群落组成的宏基因组预测。图S14：经他汀类药物处理的Pxr基因敲除（Pxr-/-）小鼠肠道菌群产生的短链脂肪酸（short chain fatty acid, SCFA）水平。图S15：PXR（pregnane X receptor）可调控他汀类药物诱导的基因表达变化。（压缩包，大小5 MB）
